Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
respiratory diseases
Biotech
GSK, Vir end flu drug alliance, removing key piece of $345M pact
The change frees Vir to “actively” pitch flu candidates to other companies while continuing to work with GSK on different respiratory pathogens.
Nick Paul Taylor
Feb 23, 2024 5:10am
After Merck's cough drama, GSK knew what to do with Bellus asset
Nov 30, 2023 8:00am
Paragonix's organ hardware show gains in heart, lung transplants
Apr 24, 2023 9:20am
Chiesi, Affibody sign $637M respiratory disease collab
Mar 7, 2023 11:15am
Clario, ArtiQ link in partnership to improve respiratory trials
Mar 2, 2023 8:00am
Sanger Institute launches virus sequencing initiative
Jan 13, 2023 7:35am